These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 639835)

  • 21. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
    Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
    Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes.
    Farrell GC; Cooksley WG; Powell LW
    Clin Pharmacol Ther; 1979 Oct; 26(4):483-92. PubMed ID: 487696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible relationship between the rate of ethanol metabolism and the severity of hepatic damage in chronic alcoholics.
    Ugarte G; Iturriaga H; Pereda T
    Am J Dig Dis; 1977 May; 22(5):406-10. PubMed ID: 857661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage.
    Sotaniemi EA; Hokkanen OT; Ahokas JT; Pelkonen RO; Ahlqvist J
    Eur J Clin Pharmacol; 1977 Dec; 12(6):429-35. PubMed ID: 598417
    [No Abstract]   [Full Text] [Related]  

  • 25. Impairment of hepatic drug metabolism in patients with acute viral hepatitis.
    Narang AP; Datta DV; Nath N; Mathur VS
    Eur J Drug Metab Pharmacokinet; 1982; 7(4):255-8. PubMed ID: 7166177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Macrocytosis and anemia in chronic alcoholism. Correlation with the results of hepatic needle biopsy].
    Gheno G; Magnabosco V; Mazzei G
    Minerva Med; 1981 May; 72(20):1301-6. PubMed ID: 7243021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver drug metabolism in patients undergoing open-heart surgery.
    Kairaluoma MI; Sotaniemi EA; Mokka RE; Nuutinen L; Kärkölä P; Larmi TK
    Scand J Thorac Cardiovasc Surg; 1979; 13(3):281-5. PubMed ID: 542833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of nifedipine on hepatic drug oxidation.
    Dickinson TH; Egan JM; Abernethy DR
    Pharmacology; 1988; 36(6):405-10. PubMed ID: 3420161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic drug metabolizing capacity of patients of cirrhosis before and after clinico-biochemical recovery.
    Chauhan CK; Nanivadekar SA; Billimoria FR
    Indian J Physiol Pharmacol; 1989; 33(1):63-6. PubMed ID: 2737749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic microsomal drug metabolism, glutamyl transferase activity and in vivo antipyrine half-life in rats chronically fed an ethanol diet, a control diet and a chow diet.
    Gadeholt G; Aarbakke J; Dybing E; Sjöblom M; Mørland J
    J Pharmacol Exp Ther; 1980 Apr; 213(1):196-203. PubMed ID: 6102148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Induction of drug-catabolizing enzymes in chronic alcoholics].
    Gundert-Remy U; Marquardt R; Andritsch F; Weber E
    Arch Biochem Biophys; 1974 Jan; 160(1):907-8. PubMed ID: 4828518
    [No Abstract]   [Full Text] [Related]  

  • 32. Correlations between cytochrome P-450 and oxidative metabolism of benzo[a]pyrene and 7-ethoxycoumarin in human liver in vitro and antipyrine elimination in vivo.
    Pelkonen O; Sotaniemi E; Tokola O; Ahokas JT
    Drug Metab Dispos; 1980; 8(4):218-22. PubMed ID: 6105054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone.
    Rautio A; Kauppila AJ; Tuimala RJ; Sotaniemi EA
    Biomedicine; 1979 Sep; 31(5):135-8. PubMed ID: 508896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure.
    Carcillo JA; Doughty L; Kofos D; Frye RF; Kaplan SS; Sasser H; Burckart GJ
    Intensive Care Med; 2003 Jun; 29(6):980-984. PubMed ID: 12698250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity.
    Sotaniemi EA; Anttila M; Pelkonen RO; Järvensivu P; Sundquist H
    Clin Pharmacol Ther; 1979 Aug; 26(2):153-61. PubMed ID: 455885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Free and total carnitine and acylcarnitine content of plasma, urine, liver and muscle of alcoholics.
    de Sousa C; Leung NW; Chalmers RA; Peters TJ
    Clin Sci (Lond); 1988 Oct; 75(4):437-40. PubMed ID: 3197375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver.
    Luoma PV; Sotaniemi EA; Pelkonen RO; Arranto A; Ehnholm C
    Eur J Clin Pharmacol; 1982; 23(3):275-82. PubMed ID: 7173298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.
    Pirttiaho HI; Sotaniemi EA; Pelkonen RO; Pitkänen U; Anttila M; Sundqvist H
    Br J Clin Pharmacol; 1980 Apr; 9(4):399-405. PubMed ID: 7378257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis.
    Fiatarone JR; Coverdale SA; Batey RG; Farrell GC
    J Gastroenterol Hepatol; 1991; 6(6):585-90. PubMed ID: 1782374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.